Two very different approaches to the same virus. Here's how they compare — and what the evidence actually supports.
What docosanol and monolaurin have in common
Both are discussed for herpes simplex, the virus behind cold sores. Both interact with membranes. That's where the similarities end.
How docosanol works
Abreva is the brand name for docosanol cream — the only FDA-approved OTC cold sore product that shortens healing time.2 It works indirectly: it absorbs into skin cells and changes their membranes so herpes simplex cannot fuse in.1 Think of it as locking the door.
The clinical results are real but modest. In the pivotal multicenter randomized placebo-controlled trial, median time to healing was 18 hours shorter in 370 docosanol-treated patients than in 367 placebo-treated patients.2 In a cold sore lesion that typically lasts 7-14 days, that is a minor reduction. It must be applied at the very first sign of a tingle — once blisters form, the window has passed.23 And a critical drug review concluded docosanol was barely more effective than its own inactive cream base.6
Docosanol also does not touch virus that has already entered cells. It blocks fusion at the surface only.1 In an animal comparison, it performed below penciclovir and acyclovir.7
How monolaurin works
Monolaurin takes the opposite approach — it goes after the virus directly. It dissolves the fatty envelope that protects herpes simplex, destroying the virus on contact rather than blocking its entry.45
This is the same membrane-disruption mechanism that makes monolaurin effective against bacteria in 443 peer-reviewed studies. For topical use, the mechanism is especially relevant: a cream or gel delivers monolaurin directly to the site where the virus sits.
The honest limitation: this has been shown in lab studies, not yet in human trials for cold sores. On paper, monolaurin's direct mechanism is more aggressive than docosanol's — it destroys the virus rather than just blocking entry — though that advantage still needs to be confirmed in people.
Monolaurin vs docosanol side by side
Docosanol
Monolaurin
Why people look for an alternative to Abreva
Docosanol works — the clinical data supports that. The modest clinical results — roughly 18 hours of improvement, and only when caught early — leave room for something that might work differently.23 But some people want options beyond a pharmaceutical cream: something with a different mechanism, a natural-origin ingredient, or something they feel better about applying long-term. That's the space monolaurin occupies. Whether the science catches up to the interest is the open question.
The honest bottom line
Docosanol has clinical trial results showing that it may work in humans when used with application guidelines provided by the manufacturer. Monolaurin has a more aggressive mechanism that directly destroys viral envelopes, with human cold sore trials still ahead of it. Neither is a cure. Docosanol is the clinically proven option today; monolaurin is the emerging approach worth watching.
Want to go deeper? Read our plain-English guide to monolaurin and cold sores.